Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
NCT ID: NCT00036127
Last Updated: 2013-11-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
INTERVENTIONAL
2002-04-30
2003-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00080327
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
NCT00325689
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
NCT00237939
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
NCT00036114
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
NCT02435836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
aripiprazole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Anaheim, California, United States
Local Institution
Cerritos, California, United States
Local Institution
Chula Vista, California, United States
Local Institution
Rosemead, California, United States
Local Institution
San Diego, California, United States
Local Institution
Atlanta, Georgia, United States
Local Institution
Macon, Georgia, United States
Local Instituton
Hoffman Estates, Illinois, United States
Local Institution
Las Vegas, Nevada, United States
Local Institution
Nashua, New Hampshire, United States
Local Institution
New York, New York, United States
Local Institution
Beachwood, Ohio, United States
Local Institution
Philadelphia, Pennsylvania, United States
Local Institution
Charleston, South Carolina, United States
Local Institution
Houston, Texas, United States
Local Institution
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007 Jan;68(1):111-9. doi: 10.4088/jcp.v68n0115.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CN138-050
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.